Novavax Inc. said it would cut nearly a third of its workforce in a sweeping restructuring of its business and the drug developer reported revenue more than halved, faring much worse than anticipated in a quarter already marred by disappointing clinical trial results.
http://on.wsj.com/2g0d1tT
No comments:
Post a Comment